<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04925284</url>
  </required_header>
  <id_info>
    <org_study_id>XB002-101</org_study_id>
    <nct_id>NCT04925284</nct_id>
  </id_info>
  <brief_title>Study of XB002 in Subjects With Solid Tumors</brief_title>
  <official_title>A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Exelixis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Exelixis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, non-randomized, open-label, multicenter, dose-escalation and expansion&#xD;
      study evaluating the safety, tolerability, PK, pharmacodynamics, and clinical antitumor&#xD;
      activity of XB002 administered IV q3w as a monotherapy to subjects with advanced solid&#xD;
      tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 7, 2021</start_date>
  <completion_date type="Anticipated">October 7, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 7, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Dose-escalation followed by cohort-expansion in tumor-specific expansion cohorts</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-Escalation Stage: MTD/recommended dose for XB002</measure>
    <time_frame>18 months</time_frame>
    <description>To determine the MTD and/or RD for further evaluation of IV administration of XB002 in subjects with advanced malignancies</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort-Expansion Stage: Objective Response Rate (ORR)</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate preliminary efficacy of XB002 by estimating the ORR per RECIST 1.1 as assessed by the Investigator</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of XB002: Adverse Events</measure>
    <time_frame>30 months</time_frame>
    <description>To evaluate the safety of XB002 through the evaluation of incidence and severity of nonserious adverse events (AEs) and serious adverse events (SAEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability of XB002 as evaluated by the duration of exposure for the study</measure>
    <time_frame>30 months</time_frame>
    <description>To evaluate the tolerability of XB002 through the evaluation of duration of exposure for the study treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability of XB002 as evaluated dose intensity of the study treatment</measure>
    <time_frame>30 months</time_frame>
    <description>To evaluate the tolerability of XB002 through the evaluation of dose intensity of the study treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>30 months</time_frame>
    <description>To evaluate the Cmax for XB002, total antibody, and free payload at scheduled visits over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Concentration (Ctrough)</measure>
    <time_frame>30 months</time_frame>
    <description>To evaluate the Ctrough of XB002, total antibody, and free payload at scheduled visits over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of XB002</measure>
    <time_frame>30 months</time_frame>
    <description>To assess the immunogenicity of XB002 as measured by anti-drug antibody (ADA) analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-Escalation Stage: Anti-tumor activity of XB002: Objective Response Rate (ORR)</measure>
    <time_frame>30 months</time_frame>
    <description>To evaluate the anti-tumor activity of XB002, as measured by ORR, per RECIST 1.1 as assessed by the Investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor activity of XB002: Duration of Response (DOR)</measure>
    <time_frame>30 months</time_frame>
    <description>To evaluate the anti-tumor activity of XB002, as measured by DOR, per RECIST 1.1 as assessed by the Investigator (dose escalation stage) or by a BIRC for selected cohorts (cohort expansion stage)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor activity of XB002: Progression Free Survival (PFS)</measure>
    <time_frame>30 months</time_frame>
    <description>To evaluate the anti-tumor activity of XB002, as measured by PFS, per RECIST 1.1 as assessed by the Investigator (dose escalation stage) or by a BIRC for selected cohorts (cohort expansion stage)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort-Expansion Stage: overall survival</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate overall survival</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">199</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Urothelial Cancer</condition>
  <condition>Epithelial Ovarian Cancer</condition>
  <condition>Cervical Cancer</condition>
  <condition>SCCHN</condition>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>XB002 Dose-Escalation Cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects (Cohort A) will accrue in cohorts of 3-12 subjects in a modified i3+3 design.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XB002 Expansion Cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The MTD or recommended dose from the dose-escalation stage may be further explored in subjects with non-small cell lung cancer [NSCLC] (Cohort B), urothelial cancer (Cohort C), epithelial ovarian cancer [EOC] (Cohort D), cervical cancer (Cohort E), SCCHN (Cohort F) and pancreatic cancer (cohort G)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XB002</intervention_name>
    <description>IV administration of XB002</description>
    <arm_group_label>XB002 Dose-Escalation Cohorts</arm_group_label>
    <arm_group_label>XB002 Expansion Cohorts</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cytologically or histologically and radiologically confirmed solid tumor that is&#xD;
             inoperable, locally advanced, metastatic, or recurrent.&#xD;
&#xD;
          -  Dose-Escalation Stage Cohort A and Cohort-Expansion Stage (Cohorts B - G): The subject&#xD;
             has received standard life-prolonging therapies unless they do not exist, or available&#xD;
             therapies are intolerable or no longer effective.&#xD;
&#xD;
          -  Cohort-Expansion Stage Cohort B (Non-small Cell Lung Cancer): Subjects with Stage IV&#xD;
             NSCLC who have documented radiographic disease progression during or following their&#xD;
             last systemic anticancer therapy.&#xD;
&#xD;
          -  Cohort-Expansion Stage Cohort C (Urothelial Cancer): Subjects with transitional cell&#xD;
             histology (including renal pelvis, ureter, urinary bladder, urethra) who have&#xD;
             documented radiographic disease progression during or following their last systemic&#xD;
             anticancer therapy.&#xD;
&#xD;
          -  Cohort-Expansion Stage Cohort D (Epithelial Ovarian Cancer): Subjects with epithelial&#xD;
             ovarian cancer, including primary peritoneal cancer (PPC) and fallopian tube cancer&#xD;
             (FTC) who have platinum-resistant disease following treatment with platinum-containing&#xD;
             chemotherapy. Note: Ovarian borderline epithelial tumors (low malignant potential) are&#xD;
             not eligible.&#xD;
&#xD;
          -  Cohort-Expansion Stage Cohort E (Cervical Cancer): Subjects with carcinoma of the&#xD;
             uterine cervix who have documented radiographic disease progression during or&#xD;
             following their last systemic anticancer therapy.&#xD;
&#xD;
          -  Cohort F (SCCHN): Subjects with head and neck cancer (squamous cell histology) who&#xD;
             have documented radiographic disease progression during or following their last&#xD;
             systemic anticancer therapy. Allowed primary tumor locations are oral cavity,&#xD;
             oropharynx, hypopharynx, glottic larynx. Note: Excluded are subjects with primary&#xD;
             tumor site of the nasopharynx.&#xD;
&#xD;
          -  Cohort G (Pancreatic Cancer): Subjects with pancreatic cancer (adenocarcinoma&#xD;
             histology) who have documented radiographic disease progression during or following&#xD;
             their last systemic anticancer therapy.&#xD;
&#xD;
          -  Expansion Cohorts: Subjects must have measurable disease per RECIST 1.1 as determined&#xD;
             by the Investigator.&#xD;
&#xD;
          -  Tumor tissue material collected approximately 2 years prior to consent. If archival&#xD;
             tumor tissue is not available, a fresh tumor biopsy may be collected from subjects&#xD;
             enrolled in the Dose-Escalation Stage and must be collected from subjects in the&#xD;
             Cohort-Expansion Stage, at least 7 days (and up to 60 days) prior to first dose.&#xD;
&#xD;
          -  Recovery to baseline or â‰¤ Grade 1 severity (Common Terminology Criteria for Adverse&#xD;
             Events version 5 [CTCAE v5]) from AEs.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.&#xD;
&#xD;
          -  Adequate organ and marrow function.&#xD;
&#xD;
          -  Sexually active fertile subjects and their partners must agree to use medically&#xD;
             accepted methods of contraception.&#xD;
&#xD;
          -  Female subjects of childbearing potential must not be pregnant at screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Receipt of prior therapies as defined in study protocol&#xD;
&#xD;
          -  Known brain metastases or cranial epidural disease unless adequately treated with&#xD;
             radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks&#xD;
             before first dose of study treatment.&#xD;
&#xD;
          -  Uncontrolled, significant intercurrent or recent illness.&#xD;
&#xD;
          -  Corrected QT interval calculated by the Fridericia formula (QTcF) &gt; 480 ms per&#xD;
             electrocardiogram (ECG).&#xD;
&#xD;
          -  Pregnant or lactating females&#xD;
&#xD;
          -  Diagnosis of another malignancy within 2 years before first dose of study treatment,&#xD;
             except for superficial skin cancers, or localized, low grade tumors deemed cured and&#xD;
             not treated with systemic therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Exelixis Clinical Trials</last_name>
    <phone>1-888-EXELIXIS (888-393-5494)</phone>
    <email>druginfo@exelixis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Backup or International</last_name>
    <phone>650-837-7400</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Site 5</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 4</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 3</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 1</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78758</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 2</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 27, 2021</study_first_submitted>
  <study_first_submitted_qc>June 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

